Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL27526817 | 0.96 | ALDH1A1 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| Ethylene SCHEMBL27581062 | 0.96 | ALDH1A1 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL27418721 | 0.91 | ALDH1A1 (0.47) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| Bicarbonate SCHEMBL8522797 | 0.89 | PTGDR2 (0.46) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| Bicarbonate SCHEMBL8522798 | 0.89 | PTGDR2 (0.46) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| Trifluoroacetic Acid SCHEMBL31133438 | 0.89 | PTGDR2 (0.50) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL6535970 | 0.85 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL1201116 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL16470387 | 0.82 | SRC (0.41) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL2378923 | 0.82 | ALDH1A1 (0.50) | ALDH1A1HPGDHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-115160154-A | Preparation method of diamine monomer with side group containing isopropyl structure and polyimide polymer thereof | 大连理工大学盘锦产业技术研究院 | 2022-10-11 | — | — | CN | claimed |
| CN-115093410-A | Preparation method of beta-carboline compound | 南京工业大学 | 2022-09-23 | — | — | CN | claimed |
| US-20190330192-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-31 | — | — | US | claimed |
| CN-102781942-B | Octahydro pyrrolo-[3,4-c] pyrroles is replaced as two of orexin receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-09-23 | — | — | CN | claimed |
| CN-102781942-A | Disubstituted octahy-dropyrrolo [3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV | 2012-11-14 | — | — | CN | claimed |
| CN-102149379-A | Methods of modulating hepatocyte growth factor (scatter factor) activity and small molecule modulator compositions of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP | 2011-08-10 | — | — | CN | claimed |
| WO-2010124055-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | claimed |
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | claimed |
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
| WO-2005047250-A1 | N-ACYLATED-3- (BENZOYL) - PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | claimed |
| EP-0092627-B1 | PROCESS FOR THE PREPARATION OF DI- OR TRIFLUOROMETHOXYPHENYL KETONES OR OF DI- OR TRIFLUOROMETHYLTHIOPHENYL KETONES | RHONE-POULENC CHIMIE (FR) | 1985-05-29 | — | — | EP | claimed |
| US-4438043-A | Process for preparation of di- or trifluoromethoxyphenyl ketones or di- or trifluoromethylthiophenyl ketones | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 76/4885HPGD 39/4885HTT 1452/4885 |
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | ALDH1A1 68/4885HPGD 83/4885HTT 2342/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | ALDH1A1 543/4885HPGD 107/4885HTT 2364/4885 |
| US-20190330192-A1 | SUBSTITUTED AZOLYLPYRROLONES AND AZOLYLHYDANTOINS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | AGPS, AASDHPPT, HPD | ALDH1A1 215/4885HPGD 709/4885HTT 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.